A Veterans Health Administration subcommittee evaluated the clinical utility of 30 pharmacogenetic tests and recommended about half for wider use.
A panel at the Biology of Genomes meeting discussed the ethical, legal, and social ramifications of germline gene editing.
The agency asked Reps. Bucshon and DeGette to consider the precertification program idea as they work on refining the draft of the Diagnostic Accuracy and Innovation Act.
Critics worry that without appropriate safeguards, DNA phenotyping will lead to discrimination while supporters see it as a tool to help investigate crimes.
President Trump had earlier in the day said on Twitter that he was considering vetoing the bill over an immigration issue and a lack of funding for a proposed Mexican border wall.
Increasing NIH funding has been a priority for Congress in recent years, despite calls from the White House to trim the agency's budget.
These lobbying efforts aim to shore up willingness among legislators to step in and halt implementation of the NCD if certain provisions remain in the final version.
At the ACLA conference this week, FDA Commissioner Gottlieb outlined his vision for the agency in the realm of LDTs.
The bill aims to reduce barriers to the use of genetic and genomic testing, including for children on Medicaid with a suspected genetic disease.
While the President's budget proposal would slash the NIH's budget by 27 percent, the White House is seeking additional funding to bring the agency's budget to its 2017 level.
The spending deal comes amid efforts by lawmakers to avoid another government shutdown, and includes lifting the national debt limit through March 1, 2019.
The registry from the American Society for Clinical Pathology aims to eventually collect metrics on how lab services impact patient outcomes.
As gene drive research is being proposed to find a solution to infectious disease outbreaks, some organizations say we must lay an ethical groundwork for its use.
NIH officials have reopened public comments through Dec. 12 on a plan to ease access to certain categories of genomic summary results.
Attendees at the recent AMP meeting grappled with issues brought to light in a lawsuit regarding the alleged negligent misclassification of a patient's genetic variant.
A lawyer and a scientist say the best result in the CRISPR patent fight would be narrow patents that prevent anyone from controlling downstream innovation.
The wide-ranging discussion with witnesses from Stanford, Johns Hopkins, and Editas Medicine touched on recent advances in research and questions of safety.
According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.